{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:44:04Z","timestamp":1758123844469,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10792-020-01290-y","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T15:03:25Z","timestamp":1579619005000},"page":"1245-1251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ocular comorbidities with direct-acting antiviral treatment for chronic hepatitis C virus (HCV) patients"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-0674","authenticated-orcid":false,"given":"Mohamed Samy","family":"Abd Elaziz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Saad Eldeen","family":"Nada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saber Hamid","family":"ElSayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada Salah","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel Galal","family":"Zaky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"issue":"9","key":"1290_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5(9):558\u2013567","journal-title":"Lancet Infect Dis"},{"key":"1290_CR2","unstructured":"Wanis H (2014) HCV treatment in Egypt\u2014why cost remains a challenge? Egyptian initiative for personal rights, Cairo, Egypt, pp 1\u20134. https:\/\/eipr.org\/en\/publications\/hepatitis-c-treatment-egypt-why-cost-remains-challenge. Accessed on 27 Aug 2018"},{"issue":"2","key":"1290_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ajg.2014.04.003","volume":"15","author":"I Waked","year":"2014","unstructured":"Waked I, Doss W, El-Sayed M (2014) The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol 15(2):45\u201352","journal-title":"Arab J Gastroenterol"},{"issue":"20","key":"1290_CR4","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN et al (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368(20):1878\u20131887","journal-title":"N Engl J Med"},{"issue":"20","key":"1290_CR5","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"I Jacobson","year":"2013","unstructured":"Jacobson I, Gordon S, Kowdley K, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E et al (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368(20):1867\u20131877","journal-title":"N Engl J Med"},{"key":"1290_CR6","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases. Society of America Recommendations for testing, managing, and treating hepatitis C. https:\/\/www.hcvguidelines.org\/. Accessed on 27 Aug 2018"},{"key":"1290_CR7","first-page":"392","volume":"63","author":"European Association for the Study of the Liver","year":"2014","unstructured":"European Association for the Study of the Liver (2014) EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 63:392\u2013420","journal-title":"J Hepatol"},{"key":"1290_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/112067210801800226","volume":"18","author":"M Fodor","year":"2008","unstructured":"Fodor M, Nagy V, Berta A, Tornai I, Pfliegler G (2008) Hepatitis C virus presumably associated bilateral consecutive anterior ischemic optic neuropathy. Eur J Ophthalmol 18:313\u2013815","journal-title":"Eur J Ophthalmol"},{"key":"1290_CR9","first-page":"545","volume":"61","author":"M Misiuk-Hoj\u0142o","year":"2007","unstructured":"Misiuk-Hoj\u0142o M, Micha\u0142owska M, Banach I (2007) Ocular manifestations during hepatitis C infection. Przegl Epidemiol 61:545\u2013550","journal-title":"Przegl Epidemiol"},{"key":"1290_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/bjo.79.2.150","volume":"79","author":"S Hayasaka","year":"1995","unstructured":"Hayasaka S, Fujii M, Yamamoto Y, Noda S, Kurome H, Sasaki M (1995) Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 79:150\u2013152","journal-title":"Br J Ophthalmol"},{"key":"1290_CR11","unstructured":"Egyptian Ministry of Health Annual Report (2007). Ministry of Health and Population website. https:\/\/www.mohp.gov.eg\/. Accessed on 27 Aug 2018"},{"key":"1290_CR12","first-page":"65","volume":"72","author":"World Health Organization","year":"1997","unstructured":"World Health Organization (1997) Hepatitis C. Wkly Epidemiol Rec 72:65\u201372","journal-title":"Wkly Epidemiol Rec"},{"issue":"3 Suppl 1","key":"1290_CR13","doi-asserted-by":"publisher","first-page":"112S","DOI":"10.1002\/hep.510260720","volume":"26","author":"G Dusheiko","year":"1997","unstructured":"Dusheiko G (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26(3 Suppl 1):112S\u2013121S","journal-title":"Hepatology"},{"key":"1290_CR14","first-page":"2291","volume":"41","author":"T Ikebe","year":"1990","unstructured":"Ikebe T, Nakatsuka K, Goto M, Sakai Y et al (1990) A case of retinopathy induced by intravenous administration of interferon. Folia Ophthalmol Jpn 41:2291\u20132296","journal-title":"Folia Ophthalmol Jpn"},{"issue":"7","key":"1290_CR15","first-page":"1077","volume":"119","author":"R Tokai","year":"2001","unstructured":"Tokai R, Ikeda T, Miyaura T et al (2001) Interferon associated retinopathy and cystoid macular edema. Arch Ophthalmol 119(7):1077\u20131079","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1290_CR16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/archopht.1993.01090030068041","volume":"111","author":"DR Guyer","year":"1993","unstructured":"Guyer DR, Tiedeman J, Yannuzzi LA (1993) Interferon-associated retinopathy. Arch Ophthalmol 111(3):350\u2013356","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"1290_CR17","first-page":"3","volume":"8","author":"K Chin-loy","year":"2016","unstructured":"Chin-loy K, Galaydh F, Shaikh S (2016) Correction: retinopathy and uveitis associated with sofosbuvir therapy for chronic hepatitis C infection. Cureus 8(7):3","journal-title":"Cureus"},{"issue":"12","key":"1290_CR18","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1111\/j.1572-0241.1998.00701.x","volume":"93","author":"S Sugano","year":"1998","unstructured":"Sugano S, Suzuki T, Watanabe M (1998) Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 93(12):2441\u20132444","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"1290_CR19","first-page":"2054","volume":"89","author":"S Sugano","year":"1994","unstructured":"Sugano S, Yanagimoto M, Suzuki T (1994) Retinal complications with elevated circulatingplasma C5a associated with interferon-alpha therapy for chronic active hepatitis C. Am J Gastroenterol 89(11):2054\u20132056","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"1290_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/jvh.12135","volume":"20","author":"A Raza","year":"2013","unstructured":"Raza A, Mittal S, Sood GK (2013) Interferon-associated retinopathy during the treatmentof chronic hepatitis C. J Viral Hepat. 20(9):593\u2013599","journal-title":"J Viral Hepat."},{"issue":"1","key":"1290_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3928\/23258160-20181212-06","volume":"50","author":"SM Elgouhary","year":"2019","unstructured":"Elgouhary SM, Said-Ahmed KE, Mowafy MA (2019) Anatomical and functional retinal complications of combined sofosbuvir and ribavirin therapy in patients with chronic hepatitis C virus. Ophthalmic Surg Lasers Imaging Retina 50(1):39\u201341","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"1290_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.25654","volume":"56","author":"S Vujosevic","year":"2012","unstructured":"Vujosevic S, Tempesta D, Noventa F, Midena E, Sebastiani G (2012) Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifiesophthalmologic screening. Hepatology 56(2):455\u2013463","journal-title":"Hepatology"},{"issue":"6","key":"1290_CR23","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s10384-009-0738-8","volume":"53","author":"ET Kim","year":"2009","unstructured":"Kim ET, Kim LH, Lee JI, Chin HS (2009) Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol 53(6):598\u2013602","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"1290_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2036.2009.04071.x","volume":"30","author":"JD Panetta","year":"2009","unstructured":"Panetta JD, Gilani N (2009) Interferon-induced retinopathy and its risk in patients with diabetesand hypertension undergoing treatment for chronic hepatitis C virus infection. Aliment Pharmacol Ther 30(6):597\u2013602","journal-title":"Aliment Pharmacol Ther"},{"key":"1290_CR25","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/bjo.85.10.1171","volume":"85","author":"K Jain","year":"2001","unstructured":"Jain K, Lam WC, Waheeb S (2001) Retinopathy in chronichepatitis C patients during interferon treatment with ribavirin. Br JOphthalmol 85:1171\u20131173","journal-title":"Br JOphthalmol"},{"key":"1290_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1167\/iovs.06-0182","volume":"48","author":"T Nagaoka","year":"2007","unstructured":"Nagaoka T, Sato E, Takahashi A, Yokohama S, Yoshida A (2007) Retinal circulatory changes associated with interferon induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci 48:368\u2013375","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1290_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jhep.2005.07.026","volume":"44","author":"L d\u2019Alteroche","year":"2006","unstructured":"d\u2019Alteroche L, Majzoub S, Lecuyer AI, Delplace MP, Bacq Y (2006) Ophthalmologic side effects during alpha-interferontherapy for viral hepatitis. J Hepatol 44:56\u201361","journal-title":"J Hepatol"},{"key":"1290_CR28","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.3748\/wjg.v12.i23.3756","volume":"12","author":"C Okuse","year":"2006","unstructured":"Okuse C, Yotsuyanagi H, Nagase Y, Kobayashi Y, Yasuda K, Koike K, Iino S, Suzuki M et al (2006) Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol 12:3756\u20133759","journal-title":"World J Gastroenterol"},{"key":"1290_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0161-6420(02)01741-4","volume":"110","author":"JA Schulman","year":"2003","unstructured":"Schulman JA, Liang C, Kooragayala LM, King J (2003) Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 110:437\u2013442","journal-title":"Ophthalmology"},{"issue":"3","key":"1290_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/ICO.0000000000000736","volume":"35","author":"AG Salman","year":"2016","unstructured":"Salman AG (2016) Ocular surface changes with Sofosbuvir in Egyptian patients with hepatitis C virus infection. Cornea 35(3):323\u2013328","journal-title":"Cornea"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01290-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-020-01290-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01290-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:12:05Z","timestamp":1611101525000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-020-01290-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1290"],"URL":"https:\/\/doi.org\/10.1007\/s10792-020-01290-y","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"type":"print","value":"0165-5701"},{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2020,1,21]]},"assertion":[{"value":"17 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest in any concept or product described in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}